Long-term safety of Mometasone Furoate administered via a dry powder inhaler in children: Results of an open-label study comparing Mometasone Furoate with Beclomethasone Dipropionate in children with persistent asthma期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Long-term safety of Mometasone Furoate administered via a dry powder inhaler in children: Results of an open-label study comparing Mometasone Furoate with Beclomethasone Dipropionate in children with persistent asthma

Authors:	Michael Noonan Jeffrey Leflein Jonathan Corren Heribert Staudinger

Institution:	(1) Allergy Associates Research Center, LLC, Portland, OR, USA;(2) Allergy & Immunology Associates, Ann Arbor, MI, USA;(3) Allergy Research Foundation, Inc., Los Angeles, CA, USA;(4) Schering-Plough Corp., Kenilworth, NJ, USA

Abstract:	Background To assess the long-term pediatric safety of 2 doses of mometasone furoate administered via a dry powder inhaler (MF-DPI) for mild-to-moderate persistent asthma and compare them with that of beclomethasone dipropionate administered via a metered dose inhaler (BDP-MDI) in the treatment of persistent asthma. Both MF-DPI doses tested are twice the approved pediatric dosage of 100 μg once-daily (QD) for children aged 4–11 years.

Keywords:
本文献已被 SpringerLink 等数据库收录！